Dergiler / art / 2021 / Cilt: 36 - Sayı: 1

Serum B cell activating factor (BAFF) and sarcoidosis activity

Dergi
art
Sayfa
72–79
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

There was no significant difference in BAFF levels between acute sarcoidosis and active chronic types.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: This study aims to determine the relationship between the severity of sarcoidosis and serum B cell activating factor (BAFF) concentrations.
📊
Temel Bulgular & Veri:Patients and methods: This cross-sectional study was conducted between December 2015 and March 2018 on 55 patients with sarcoidosis (16 males, 39 females; mean age: 39.9; range, 25 to 60 years) and 28 healthy subjects (7 males, 20 females; mean age: 39; range, 25 to 60 years).
💡
Sonuç & Katkı:There was no significant difference in BAFF levels between acute sarcoidosis and active chronic types.
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:2015 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: This study aims to determine the relationship between the severity of sarcoidosis and serum B cell activating factor (BAFF) concentrations. Patients and methods: This cross-sectional study was conducted between December 2015 and March 2018 on 55 patients with sarcoidosis (16 males, 39 females; mean age: 39.9; range, 25 to 60 years) and 28 healthy subjects (7 males, 20 females; mean age: 39; range, 25 to 60 years). The sarcoidosis patients were divided into active chronic sarcoidosis and acute sarcoidosis groups. The diagnosis of sarcoidosis was based on clinical, radiological, and pathologic findings. Also, the diagnosis of the active disease was based on the level of angiotensin-converting enzyme, active skin, eye, and lung lesions. Scadding score was also measured, and other patient information was collected by pre-designed questionnaires. Results: The most involved organs were the skin (92.7%) and joints (92.3%), respectively. The mean BAFF concentration in both active chronic sarcoidosis (p=0.001) and acute sarcoidosis (p=0.001) groups was significantly higher than the control group, but the mean level of BAFF in these two groups was not significantly different (p=0.351). Between two groups of patients, only calcium (p=0.001) and forced vital capacity (p=0.021) were higher in the acute group of sarcoidosis. Also, among the factors associated with active chronic sarcoidosis and acute sarcoidosis, none was significantly correlated with BAFF. Conclusion: Serum BAFF concentration was higher in patients with sarcoidosis, while this was not significantly different from increasing severity of symptoms. There was no significant difference in BAFF levels between acute sarcoidosis and active chronic types.

🔖

Bu Makaleye Atıf Yap

HASHEMZADEH, K., FATEMIPOUR, M., MIRFEIZI, S. Z., JOKAR, M., SARABI, Z. S., FARD, M. H., RAFATPANAH, H., KHODASHAHI, M. (2021). Serum B cell activating factor (BAFF) and sarcoidosis activity. art, Cilt: 36 - Sayı: 1, 72–79. https://ajindex.com/articles/351616

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011;305:391-9
  2. Ando M, Goto A, Takeno Y, Yamasue M, Komiya K, Umeki K, et al. Significant elevation of the levels of B-cell activating factor (BAFF) in patients with sarcoidosis. Clin Rheumatol 2018;37:2833-8
  3. Fazel SB, Howie SE, Krajewski AS, Lamb D. B lymphocyte accumulations in human pulmonary sarcoidosis. Thorax 1992;47:964-7
  4. Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006;15:570-6
  5. Dasilva V, Breuil V, Chevallier P, Euller-Ziegler L. Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFalpha blockade. Efficacy of rituximab, report of a single case. Joint Bone Spine 2010;77:82-3
  6. Rauch M, Tussiwand R, Bosco N, Rolink AG. Crucial role for BAFF-BAFF-R signaling in the survival and maintenance of mature B cells. PLoS One 2009;4:e5456
  7. Stohl W, Xu D, Kim KS, Koss MN, Jorgensen TN, Deocharan B, et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005;52:2080-91
  8. Pertschuk LP, Silverstein E, Friedland J. Immunohistologic diagnosis of sarcoidosis. Detection of angiotensin-converting enzyme in sarcoid granulomas. Am J Clin Pathol 1981;75:350-4
  9. Lawrence EC, Brousseau KP, Berger MB, Kurman CC, Marcon L, Nelson DL. Elevated concentrations of soluble interleukin-2 receptors in serum samples and bronchoalveolar lavage fluids in active sarcoidosis. Am Rev Respir Dis 1988;137:759-64
  10. Visser H, Vos K, Zanelli E, Verduyn W, Schreuder GM, Speyer I, et al. Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors. Ann Rheum Dis 2002;61:499-504
  11. Ueda-Hayakawa I, Tanimura H, Osawa M, Iwasaka H, Ohe S, Yamazaki F, et al. Elevated serum BAFF levels in patients with sarcoidosis: association with disease activity. Rheumatology (Oxford) 2013;52:1658-66
  12. Saussine A, Tazi A, Feuillet S, Rybojad M, Juillard C, Bergeron A, et al. Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PLoS One 2012;7:e43588
  13. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002;2:465-75
  14. Do RK, Hatada E, Lee